Background The cost of topical treatments for actinic keratosis (AK) has historically been evaluated in relation to the
Introduction
Actinic keratosis (AK) is a skin condition characterized by chronic cutaneous lesions, caused by exposure to ultraviolet light. 1 Their presence is considered a risk factor for skin malignancies. AK occurs on sun-exposed areas of the body, such as the head, neck and forearms 2 and primarily affects the elderly population. In Europe, the overall prevalence of AK is estimated to range between 6% and 26%, with a higher prevalence in southern countries. 3 Actinic keratosis lesions are precancerous and may evolve into invasive squamous cell carcinoma (iSCC). While historically the risk of progression was believed to be dependent on the clinical classification of lesions (measured by the Olsen et al. score), recent research suggests that it does not accurately assess their underlying histology, 3 and therefore is not indicative of the risk of progression towards iSCC. 4 Currently, the goal of AK therapy is to treat all lesions, irrespective of their thickness. However, there is a recent paradigm shift in the treatment of multiple lesions (≥5) in an anatomical area, where lesion-targeted therapy is no longer believed appropriate due to possible field cancerization. There is a growing consensus that in such cases the treatment should aim at treating every AK lesion as well as the surrounding photo-damaged skin. [5] [6] [7] Evidence for this is also the recently developed field-directed 'actinic keratosis area and severity index' (AKASI) which allows for the quantitative evaluation of AK severity across the entire affected area of the head. 8 Therefore, for multiple lesions, the real cost of topical treatments depends on the size of the cancerization area which requires treatment, rather than on the number of AKs. There is, however, a disconnection between the real cost incurred when treating the full cancerization area and the cost attached to different topical options in past economic evaluations. Previous cost-effectiveness studies focused on cost per lesion or cost per pack of medication instead of examining the area of cancerization and quantity of treatment used. Aguilar et al.
9 estimated the quantity of MAL cream by evaluating the weight consumed to treat lesions; a cost per tube was applied. Similarly, Annemans et al. 10 calculated the total cost of care and the cost per lesion in AK patients, by multiplying each item with its unit cost. This method of costing per lesion/per pack in AK is consistent in the literature.
9-12
The main objective of this study was to estimate the true cost of topical treatments for the management of AK with multiple lesions in Italy by looking at the quantity of topical drug needed as a function of the cancerization area.
Materials and methods
Treatment options for AK include destructive therapies [e.g., surgery, cryotherapy, dermabrasion, photodynamic therapy (PDT)], topical medications [e.g., topical fluorouracil (5-fluorouracil, 5-FU), imiquimod, ingenol mebutate, diclofenac], and chemical peels (e.g., trichloroacetic acid). The focus of this study was on topical treatments for the management of multiple AK lesions in Italy.
Topical treatments indicated for the treatment of AK currently available in Italy are similar to those available in other European countries and include the following:
• Metvix â : 16% methyl aminolevulinate photodynamic therapy (MAL PDT), which requires illumination of a red light source or daylight. Currently available as 1 tube (2 g) package. 13 • Table 1 outlines the relevant data and assumptions. In order to evaluate the actual cost of each treatment, the official approval status of the drug was used to estimate the amount of cream needed per one cm 2 . If the summary of product characteristics (SmPC) did not provide guidance on the maximum area covered per application, it was assumed that 250 mg/ 25 cm 2 topical treatments were applied on the cancerization area. The cost of treatment was calculated based on the total area treated (i.e., the area of the cancerization field), and the quantity of treatment used to effectively treat this area. To understand how much cream was needed to cover the cancerization area of a certain size, it was essential to calculate what surface a tube/sachet of cream could cover and check if any restrictions based on the SmPC were in place. Therefore, to understand the cost incurred with each of these treatments, the corresponding SmPCs were reviewed for relevant posology information related to: (i) the maximum treatment area allowed in a single session and (ii) the maximum allowed quantity per application.
According to the SmPC, Metvix â did not have any restrictions on the surface which could be treated during one session. Finally, the SmPC of Solaraze â did not provide specific restrictions related to the maximum area which could be treated per day. However, it provided guidance which allows for its estimation. According to the SmPC, a maximum daily dose of 8000 mg (8 g ) is indicated and should not be exceeded. The suggested treatment duration is 60-90 days and the cream needs to be applied twice a day during this period. It was assumed that to achieve full efficacy, the 90-day period of treatment will be required. In addition, the SmPC states that 'normally, 0.5 g (the size of a pea) of the gel is used on a 5 cm 9 5 cm lesion site'. To estimate the cost per area treated with each topical option, the ex-factory discounted price was used. This is the price paid Description: Product characteristics of the topical treatments available in Italy, according to their SmPCs, including restrictions on maximum area allowed to be treated or maximum quantity of cream to be applied.
by the Italian NHS to companies if their drug is used outside of the hospital setting; it is published in the official journal of the Italian government, the Gazzetta Ufficiale. As this is the price covered by the Italian NHS, it was assumed to be more appropriate than the list price, which would only be relevant for the private setting. The ex-factory prices applied in the current analysis are listed in Table 1 . As Metvix â is used on an outpatient basis and is, therefore, not reimbursed by the NHS for use outside of the hospital setting, its discounted price paid by the hospitals was applied in the analysis. The estimated cost per cm 2 treated allowed for a better understanding of the true cost of treatment in relation to the size of the area treated. To illustrate this, six hypothetical sizes were evaluated and the cost of treating each one of them with the available treatment options was estimated.
Results
The analysis estimated the number of tubes/sachets needed for the treatment of the cancerization area of a certain size and then estimated the total costs, based on the ex-factory price. Outlined in Table 2 is the number of tubes/sachets that cover a specific surface area, broken down by treatment option. For example, 100 cm 2 is estimated to approximate the treatment of a full cheek. Table 3 reports the total cost of treating different parts of the head, taking into account the ex-factory price and the number of packages needed to cover an area of a certain size. It is evident from Table 2 and Table 3 and Solaraze â now being the most expensive option at €522. In addition to the cost of treatment, the analysis further calculated the duration of treatment with each topical option, based on the maximum area size to be treated per cycle. The estimated treatment duration by area size, taking into account the maximum allowed area size to be treated, is reported in 
Discussion
This study demonstrates that the price of treatment depends on the cancerization field and, therefore, the quantity of treatment used per area should be considered. We evaluated the cost of the available topical treatments for multiple AKs in Italy, while considering the size of the cancerization area, in line with the price per dose needed to cover the cancerization area. Based on the information provided in the SmPCs of the evaluated treatment options, the area which could be treated with a single pack of However, for the treatment of cancerization areas larger than 100 cm 2 Metvix â was the second cheapest treatment option, preceded only by Zyclara â . As the European Medicines Agency (EMA) is responsible for the regulations for the use of drugs in the Europe Union, these calculation can be easily replicated for other European countries as far as the local costs are applied. In addition to being one of the least expensive options, the duration of treatment with Metvix â was also significantly shorter, compared with the rest of the treatments. The estimated length of treatment is an important factor by itself and is indicative of the duration of discomfort and the need for topical medications with impairment on social and working activities. In the literature, treatment duration was reported to be associated with significantly reduced adherence and persistence during treatment, 18 and the development of treatment options with shorter treatment duration has been recommended by experts. 19 In addition, other factors including efficacy, level of pain, and adverse events also have an impact on the choice of treatment by dermatologists, however, this information has been well documented in published RCT studies. Therefore, the current analysis focused solely on the two factors that have not previously been discussed: the calculation of cost of the drug per treated area and the length of treatment.
Conclusion
The current study demonstrated that changing treatment costing strategies in the management of multiple AKs towards costing per cancerization area instead of costing per lesion, is a much more accurate representation of the 'real world cost' for actinic keratosis. This conclusion is expected to have implication on the reimbursing decisions, in addition to the corresponding efficacy of the treatments. Currently, the reimbursement status of topical treatments in Italy is not consistent. 
